Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810

Inclusion Criteria

• •Main criteria for inclusion:
• •1. Adult male or female Chinese subject aged 18 to 70 years, inclusive, at the time of signing the informed consent form, with weight at least 40 kg when screening.
• •2. Life expectancy ≥ 12 weeks as judged by the Investigator.
• •3. Histologically or cytologically confirmed, locally advanced or metastatic solid tumor and be limited to:
• •* Gastric carcinoma (including gastro-oesophageal junction adenocarcinoma).
• •* Hepatocellular carcinoma (Child-Pugh Class A).
• •* Undifferentiated nasopharyngeal carcinoma.
• •4. Each subject should provide at least 5 slides for the formalin fixed and paraffin embedded tumor biopsy (undyed) at the baseline, fresh biopsy or most recent primary tumor sample or metastatic sample is required.
• •5. Patients, who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists.
• •6. Toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤ 1 as per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), excluding alopecia and peripheral neuropathy. For subjects having a prior platinum-based therapy, peripheral neuropathy are required to recover to ≤ CTCAE grade 2.
• +54 more criteria